Achillion Pharmaceuticals (NASDAQ:ACHN) is up 15.7% in robust postmarket action after the Federal Trade Commission granted early termination of the HSR waiting period in its acquisition by Alexion Pharmaceuticals (NASDAQ:ALXN).
Achillion shareholders voted to adopt the deal – a $6.30/share bid – at a special meeting on Dec. 19.
https://seekingalpha.com/news/3534513-achillionplus-15_7-after-ftc-deal-clearance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.